바이오카디아BCDA 주가

♻️ 재탕[8-K] 중대 사건 — FORM 8-K

BioCardia Announces Presentation Of Data From CardiAMP Minimally-Invasive Chronic Myocardial Ischemia Treatment Trial Demonstrating Positive Clinical Outcomes

Results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimally invasive CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major adverse cardiac events

♻️ 재탕[4] 내부자 거래 — FORM 4

♻️ 재탕[8-K] 중대 사건 — FORM 8-K

♻️ 재탕[4] 내부자 거래 — FORM 4

♻️ 재탕BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript

BioCardia, Inc. (BCDA) Q1 2026 Earnings Call May 15, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman - CEO,...

♻️ 재탕Transcript : BioCardia, Inc., Q1 2026 Earnings Call, May 15, 2026

Presentation Operator MessageOperator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia 2026 First Quarter Financial Results and Business Update

BioCardia Q1 2026 Earnings Call: Complete Transcript

BioCardia Inc (NASDAQ:BCDA) Q1 Earnings Miss Overshadows Clinical Progress

BioCardia Q1 2026 earnings miss with EPS of -$0.21 overshadowed clinical progress. Stock down 0.8% pre-market amid focus on cash burn and trial advancements.

BioCardia Q1 EPS $(0.21) Misses $(0.17) Estimate

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 64.41 percent increase over losses of $(0.59) per share from the